Spinraza (Nusinersen) Approved by FDA for SMA Patients - Ionis Pharmaceuticals / Biogen

Spinal Muscular Atrophy 2019: Approved Treatment and Upcoming Therapeutic StrategiesПодробнее

Cure SMA Webinar on Spinraza(TM) Approval - U.S. OnlyПодробнее

Spinraza (nusinersen) ApprovalПодробнее

The Development Journey of Spinraza® (nusinersen): From Advocacy to Treatment and BeyondПодробнее

Nusinersen (SpinrazaTM): The First FDA Approved Treatment for SMAПодробнее

SMA drug Spinraza approved by FDAПодробнее

FDA approves SMA drug SpinrazaПодробнее

Biogen and Ionis Surge as Childhood Spine Disorder Drug Passes Pivotal StudyПодробнее

FDA approves SMA drugПодробнее

SPINRAZA® (nusinersen) Mechanism of Action in Spinal Muscular AtrophyПодробнее

Prix Galien USA 2017 / Best Biotechnology Product: Biogen & Ionis Pharmaceuticals SPINRAZA®Подробнее

Cure SMA Spinraza Access Update Webinar 2.14.17 - U.S. OnlyПодробнее

How Spinraza (nusinersen) and Evrysdi treat Spinal Muscular Atrophy (SMA) through splice-switchingПодробнее

Biogen: EMA and FDA Progress (Nov 2016)Подробнее

Nusinersen Clinical Trial DataПодробнее

Nusinersen Treated Type 1 Patients Older Than 7 MonthsПодробнее

SMA type 3 adult going in for NEW spinraza drug treatmentПодробнее

Nusinersen Treatment for Older Patients with SMAПодробнее

SPINRAZA: FDA одобрило первый препарат для спинальной мышечной атрофииПодробнее